Pfizer Ends Development Of Quinolone Antibiotic DK-507k
This article was originally published in The Pink Sheet Daily
Pfizer is discontinuing development of quinolone antibiotic DK-507k
You may also be interested in...
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states
Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.